Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3)	11/3/2005 2:49:55 PM
From: tuck	Read Replies (1) \| Respond to of 507

PDUFA date extended to late January: SAN CARLOS, Calif.--(BUSINESS WIRE)--Oct. 28, 2005--Nektar Therapeutics (Nasdaq:NKTR - News) reported today that Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said today that the U.S. Food and Drug Administration has notified the companies that it is extending its original review period for Exubera® (insulin (rDNA origin) powder for oral inhalation) by three months to review additional technical chemistry data submitted by the companies. In September, an FDA Advisory Committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. FDA is not obligated to follow the Advisory Committee's recommendation, but usually does so. Pfizer and sanofi-aventis continue to work closely with the FDA so that this important medicine can be made available for patients.<< snip I guess this didn't come as a big surprise, as the share price seems more or less unaffected. Cheers, Tuck